Jiacheng Yan - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Jiacheng Yan

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Cell Reports|April 7, 2015

NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancerCollin M Blakely, Evangelos Pazarentzos, Victor Olivas, et al.

Cancer Cell|April 16, 2015

AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomasMoshe Elkabets, Evangelos Pazarentzos, Dejan Juric, et al.

Nature Genetics|February 10, 2015

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapiesLuping Lin, Amit J Sabnis, Elton Chan, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Cell Reports|April 7, 2015

NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancerCollin M Blakely, Evangelos Pazarentzos, Victor Olivas, et al.

Cancer Cell|April 16, 2015

AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomasMoshe Elkabets, Evangelos Pazarentzos, Dejan Juric, et al.

Nature Genetics|February 10, 2015

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapiesLuping Lin, Amit J Sabnis, Elton Chan, et al.

Pageof 2